Eye Disease & Ophthalmology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

This completed Phase III study explored a new way to deliver ranibizumab through an implant for people with diabetic retinopathy who do not have swelling in the center of the retina. The results, collected from multiple sites in the United States and Puerto Rico, could lead to longer-lasting treatments that reduce the need for frequent eye injections. This would make managing diabetic retinopathy easier and less burdensome for patients.

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This ongoing Phase 3 trial is testing a long-term implant that continuously delivers ranibizumab for patients with neovascular age-related macular degeneration, a common cause of vision loss in older adults. By providing a steady supply of the medicine, the implant could reduce how often patients need eye injections. The study is recruiting worldwide, including patients who have finished earlier related trials, aiming to confirm safety and effectiveness over time.

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

This Phase 3 study tested a higher dose of aflibercept injections in 333 participants with diabetic macular edema in China. If effective, this stronger dose may reduce how often patients need injections, improving convenience and quality of life for people managing this diabetes-related eye condition. The results will help guide future treatment plans in this population.

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

This Phase 3 trial is studying a refillable implant that delivers ranibizumab for people with neovascular age-related macular degeneration. The implant can be refilled every 36 weeks, potentially meaning fewer visits for injections. The trial is actively recruiting across multiple countries and aims to provide important information on how well this approach works and its safety over longer periods.

MMP-9 Inhibition for Recalcitrant Wet AMD

This Phase 2 study is testing an oral antibiotic called doxycycline for patients with wet age-related macular degeneration who do not fully respond to standard eye injections. The goal is to reduce persistent fluid in the retina that can harm vision. The study is recruiting adults in the United States and may offer a new option for those needing additional treatment beyond current therapies.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.